Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 13,601–13,700 of 15,747
NVX-CoV2373 Efficacy in Preventing SARS-CoV-2 Infection in AdolescentsPreprint
Deming, M. E., Brown, E. R., McArthur, M. A., Schrag, S. J., Arvay, M. L., Humphrys, M. S., Ravel, J., Adelglass, J. M., Essink, B. J., Musante, D. B., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4669162
Vaccine Disease-Prevention Efficacy Studies: Traditional Approaches and New Frontiers
Patterson, S., & Beckers, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65937-9_13
Kim, S., Park, S. H., Choi, S., Lee, W., Choi, S., Han, S., Han, S., & Lee, D. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2467554 · Cited by 2
Regulatory and translational challenges in biotechnology-driven drug delivery
Suryawanshi, S. S., Patil, V. M., Kudale, P. P., Nangude, M. S., Doke, R. R., Patil, P. P., Muleva, G., Vinchurkar, K., Kothawade, S. N., & Mendhi, S. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40620-1.00006-6 · Cited by 1
Rich dynamics and data analysis of immune decline against SARS-CoV-2
Wang, Z., Jing, S., Xiang, H., et al. (2026) · Advances in Continuous and Discrete Models · doi:10.1186/s13662-026-04069-0
The RNA World: The Best of Times, the Worst of Times
VandenDriessche, T. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29173.tvd
Owen, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-30904-5_5
Raja, H. A., Malik, F. N., Fatima, H., & Babar, M. M. (2026) · Springer eBooks · doi:10.1007/978-981-95-3957-4_25
Sakaya, K., Ishikawa, T., Okai, M., et al. (2025) · Pediatrics International · doi:10.1111/ped.70065
Language and racial disparities in COVID-19 vaccination during pregnancy and lactation
Ukah, U. V., Haapala, J. L., Benítez, G. V., DeSilva, M. B., Vesco, K. K., Daida, Y. G., Sidebottom, A., Kharbanda, E. O., Ehresmann, K., Seburg, E. M., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128638
Huang, D., Chen, C., Wei, X., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3920236
Les vaccins à ARN messager anti-Covid-19
Reynes, J. (2023) · Actualités Pharmaceutiques · doi:10.1016/s0515-3700(23)00475-5
Likelihood of COVID-19 reinfection in an urban community cohort in Massachusetts
Casey, S. M., Legler, A., Hanchate, A. D., & Perkins, R. B. (2022) · Dialogues in Health · doi:10.1016/j.dialog.2022.100057 · Cited by 1
“However, susceptibility to reinfection increases over time following both infection and from immunization.(3,4,17,55) More research is needed to understand the dynamics of immunity from infection and vaccination.”
Niwa, T., Onishi, Y., Tamura, M., Kasuya, Y., Nishiya, T., Sugiyama, D., Yoshida, T., Tozuka, M., Namba, E., Miyaji, K., et al. (2026) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2026.2615355 · Cited by 1
Jasim, W. M., Al-Dewachi, A. B., Ahmad, W. G., et al. (2026) · Communications in computer and information science · doi:10.1007/978-981-92-4305-1_9
MicroRNAs in Penile Cancer: A Systematic Review of Diagnostic, Prognostic, and Mechanistic Evidence
Zhang, X., Rahman, F., Kelly, J. D., et al. (2026) · European Urology Focus · doi:10.1016/j.euf.2026.06.028
Palma, P., Emili, E., Pighi, C., Colantoni, N., Morrocchi, E., Pascucci, G. R., Rivalta, B., Rotulo, G. A., Rossetti, C., Santilli, V., et al. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2661495
“4,5 However, variability in vaccine response across different populations, particularly among individuals with compromised immune systems, remains underexplored.”
Milojevic-Ilic, M. (2023) · Medicinski pregled · doi:10.2298/mpns2308217m
Development Of mRNA Vaccines And Therapeutics Beyond Covid-19
Yadav, A., Dwivedi, A., & Darwhekar, G. N. (2025) · European journal of parenteral & pharmaceutical sciences · doi:10.37521/ejpps30211
COVID-19 vaccination predictors among people with mental disorders
Novaković, E., Stojanović-Tasić, M., Novaković, T., et al. (2024) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh230915010n
Laha, S., & Chatterjee, R. (2021) · medRxiv · doi:10.1101/2021.02.08.21251359
Serologic survey for toxoplasmosis in bats: a preliminary study in Brazil.
Fornazari, F., Langoni, H., Köfer, J., & Schobesberger, H. (2011)
Vaccination against COVID-19 in a post-pandemic era
Neto, F. L., Ceccato, A., & Ranzani, O. (2024) · European Respiratory Society eBooks · doi:10.1183/2312508x.10020223
Editorial: Cardiovascular complications of COVID-19
Marian, A. J. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000846
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0014
COVID-19 pandemic - Is the bright sun in sight?
Hygriv Rao, B., & Kakarla, S. (2020) · Journal of Medical and Scientific Research · doi:10.17727/jmsr.2020/8s1-e1
Okholm, A. K., Fougeroux, C. E., Hagen, S. H., Paludan, S. R., Nielsen, M. A., de Jongh, W. A., & Sander, A. F. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.129117 · Cited by 1
The Solutions Come from Science and Knowledge
Czernin, J. G., & Radu, C. G. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.261792
Ryu, H. E., Yoon, J., Choi, J., Heo, S., Hong, K., & Jung, D. (2024) · Vaccines · doi:10.3390/vaccines12060626 · Cited by 1
Chettri, D., Desai, A., Khan, S., et al. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns2.6145
Che-Kamaruddin, N., Johari, J., Yahaya, H., Zainal, N., Nguyen, H. C., Hontz, R. D., Letizia, A. G., & AbuBakar, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1921846
Fuchs, T., Appelt, D., & Ellemunter, H. (2024) · Vaccines · doi:10.3390/vaccines12010098
“Two anti-SARS-CoV-2 vaccines based on mRNA technology (Comirnaty ® (BNT162b2), Pfizer—BioNTech (New York, NY, USA) and Spikevax ® (mRNA-1273), Moderna—NIAID (London, UK)) have been approved [10,11].”
BackgroundFarrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0003
Jasim, R. A., Noori, S. S., Mahmood, A. S., Jumaa, A. W., & Alkareem, F. Z. A. (2023) · Academia Open · doi:10.21070/acopen.8.2023.7843
6 important truths about COVID-19 vaccines
Lynch, S. E., & Nagaraju, K. (2021) · doi:10.64628/aai.a6934rkum
Longitudinal functional lung imaging in children with Post-COVID-19 syndrome
Kraus, C., Tan, L., Hinsen, M., Schmidt, S., Nedoschill, E., Wachter, F., Mandelbaum, H., Wagner, A. L., Schöffl, I., Weigelt, A., et al. (2026) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-025-00216-x
“The introduction of vaccines in late 2020 led to a reduction in overall mortality and patients requiring intensive care [2, 3], shifting the focus toward the long-term sequelae of the infection [4, 5].”
Ou, B., Tang, X., Qian, S., Chen, B., Fang, S., Su, J., Sheng, X., Feng, J., Yuan, Z., & Zhang, J. (2026) · Small · doi:10.1002/smll.74730
The Impact of Gut Microbiota on the Immune Response to Vaccination
Bajoria, V., Szczelkun, A., Dinse, T., van Overveld, F. J., & Rijkers, G. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00051-6 · Cited by 1
ZoghAli, M., Hojjati, F., Mirenayat, M. S., & Rayegani, S. M. (2024) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2024.101691 · Cited by 1
Lignitz, S., & Zepp, F. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1140-1093
Hara, S., Arase, S., Suzuki, T., Mizogaki, I., Miyazaki, T., Kubara, K., Ida, Y., Kondo, K., Arai, K., Suzuki, Y., et al. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108488 · Cited by 2
Montecalvo, M. A., Visintainer, P., Drugge, E. D., Kowalski, K., Raffa, R., McKenna, D. F., Moronta, C., & Wormser, G. P. (2024) · Vaccines · doi:10.3390/vaccines12030327
“When the EUAs were issued, the vaccine efficacy for preventing symptomatic SARS-CoV-2 infection was 95% and 94.1% for the Pfizer-BioNTech and Moderna vaccines, respectively [1,2].”
MethodInfluentialA Simple Method to Evaluate the Length of Poly(A) Tails in mRNA
Mumenthaler, J., Feldmann, M., Mamaghani, S., Penna, R. R., Frei, J., Jarzebska, N., Mellett, M., Guenova, E., Kündig, T. M., Läuchli, S., et al. (2026) · Methods and Protocols · doi:10.3390/mps9040109
“The synthesis of mRNA, such as that used in approved vaccines against SARS-CoV2 [1–3] or Respiratory Syncytial Virus (RSV) [4], as well as in many new drugs currently under development [5,6], is achieved by in vitro transcription (ivt) of a DNA template [7], initially using purified RNA polymerase…”
Randomized Controlled Trials Under Influence: Covariate Factors and Graph-Based Network InterferencePreprint
Schwarz, T. C. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2111.14263 · Cited by 2
Lacedonia, D., Scioscia, G., Giganti, G., Santoro, A., Tondo, P., & Barbaro, M. P. F. (2022) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002521
Vaccinationism in the modern era: The fight against the new “unorthodoxy”
Rees, A. R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43876-9.00014-4
Mecanismo y diseño de vacunas para el sars-cov-2, revisión narrativa
Ochoa, J. E. S., Cueto, M. C. S., & Padilla, A. C. (2024) · Medicina UPB · doi:10.18566/medupb.v43n1.a10 · Cited by 1
Herramientas biotecnológicas en el diagnóstico, prevención y tratamiento frente a pandemias
Molina, P., & Arias, M. T. (2021) · Bionatura · doi:10.21931/rb/2021.06.03.33
Persano, I., Cani, M., Rio, B. D., Ferrari, G., Garbo, E., Parlagreco, E., Pisano, C., Cetoretta, V., Delcuratolo, M. D., Turco, F., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11010165
“7% of CPs after the second dose versus 51% of healthy individuals aged 55 and older [8].”
Background13. Lære av kriser: om diskrepanserfaringer, svarevne og pandemihåndtering
Lindstrøm, J. A. (2025) · Universitetsforlaget eBooks · doi:10.18261/9788215074078-25-13
la Vega, R. E. D. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230621rv
Diallo, F., Der, M., Thiam, S., Diop, F. B., Sarr, N. F. M., Diouf, M. A., Gaye, A. A., NIANG, A. A., Diop, A., Dieye, B., et al. (2025) · World Journal of Vaccines · doi:10.4236/wjv.2025.154004
Pizzichetti, C., Latino, I., Virgilio, T., Capucetti, A., Chahine, K., Cascione, L., Moro, S. G., Bilato, G., Brügger, M., Kozarac, N., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106432
Harrison, D. A., Watkinson, P., Doidge, J., Shankar‐Hari, M., Mouncey, P. R., Patone, M., Coupland, C. A. C., Hippisley‐Cox, J., & Rowan, K. (2022) · medRxiv · doi:10.1101/2022.10.03.22280649
“Randomised controlled trials of vaccine efficacy inevitably have relatively low numbers of critical care admissions,(8-10) but recent population studies suggest that vaccination reduces the risk of admission for critical care.”
BackgroundNavarro, B. O. (2023) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/192635
Microcondensate‐Mediated Intracellular Infusion of mRNA Across the Plasma Membrane
Kawaguchi, Y., Kikkawa, A., Kimura, S., Abe, H., & Futaki, S. (2025) · Angewandte Chemie · doi:10.1002/ange.202512139
Dadabhai, S. S., Samandari, T., Zhang, B., Hudson, A., Mkhize, N. N., Tapley, A., Andriesen, J. G., Moore, P., Chirenje, Z. M., Elyanu, P., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10935317/v1
Considerations in Designing Clinical Trials of Novel Antibacterial Agents Using a Superiority Design
Paterson, D. L., Melnick, D., Dane, A. L., Goldberger, M. J., Schramm, M., Huang, S. S., Moore, N., Hardy, M. J., Chiang, S. L., Uria-Nickelsen, M. R., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag207
Ansari, A. I., Abbas, M., Rizvi, A. A., Afreen, S., Verma, S., Mehdi, M., Verma, S., & Mahdi, F. (2024) · Coronaviruses · doi:10.2174/0126667975285693240427073251
Kakisaka, K., Suzuki, Y., Yoshida, Y., & Takikawa, Y. (2021) · Kanzo · doi:10.2957/kanzo.62.613
Kaplan, B., Pavel, S. T. I., Uygut, M. A., Tunc, M., Eröksüz, Y., Çelik, İ., EREN, E. E., Korukluoğlu, G., Kara, A., Özdarendeli, A., et al. (2025) · Vaccines · doi:10.3390/vaccines13020169 · Cited by 1
“RNA vaccines developed by Moderna and Pfizer-BioNTech, which encode the spike protein, have shown high efficacy in clinical trials [11,12].”
Interstitial Lung Disease With Respiratory Failure After COVID-19 mRNA Vaccination
Maruyama, S., Takahashi, T., Kobayashi, D., Hayase, Y., & Sugiyama, Y. (2024) · Cureus · doi:10.7759/cureus.58491 · Cited by 1
The COVID-19 Pandemic’s Effect on Dental Students’ Attitude and Habits About Oral Hygiene
Özişçi, Ö., & Küçükeşmen, H. C. (2026) · SDÜ Tıp Fakültesi Dergisi · doi:10.17343/sdutfd.1736409
Jobim, M., Garcia, T. S., Ewald, G. M., Sekine, L., Parolo, É., Pellegrini, J. A. S., Schwarz, P., dos Santos, N. A. D., Schuler, L., & Jobim, L. F. J. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200056
Direct and Indirect Effects of Vaccines: Evidence from COVID-19
Freedman, S. M., Sacks, D. W., Simon, K. I., & Wing, C. (2025) · American Economic Journal Applied Economics · doi:10.1257/app.20230717 · Cited by 2
(2000) · Time to knit · doi:10.1016/s1877-7856(22)43280-6
What is mRNA COVID 19 Vaccine and What is the safety and Efficacy of mRNA COVID 19 Vaccine?Preprint
Mukherjee, D. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/hck6r · Cited by 1
Humoral Immunogenicity of SARS-CoV-2 mRNA Primary Vaccination Among People with HIV
Nomah, D. K., Robles, A. G., Bruguera, A., Tiraboschi, J. M., Benet, S., García‐Pérez, J., Jiménez, P., Vilaró, I., Navarro, G., Sánchez‐Palomino, S., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14040893
“Vaccination has played a central role in reducing the burden of severe COVID-19 globally [5]. mRNA vaccines such as BNT162b2 and mRNA-1273 showed high efficacy in randomized clinical trials conducted in the general population [6,7].”
Sharma, P., Sijapati, M. J., Gautam, S., et al. (2022) · Nepalese Respiratory Journal · doi:10.3126/nrj.v1i1.45234
Advancing regenerative medicine with RNA nanotechnology for chronic and end organ diseases
Bakrania, A. K., Lefebvre, A.-T. N., de Vries, R., Laflamme, M. A., Jaeckel, E., He, H. H., Radvanyi, L. G., Hedtrich, S., Sahay, G., Blakney, A. K., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01476-y · Cited by 3
Gregersen, C. H., Mearraoui, R., Søgaard, P. P., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4604235
Koumi, K., Jeon, S., & Lee, Y. S. (2026) · Epidemiologia · doi:10.3390/epidemiologia7020045
“Research highlights that misinformation and longstanding distrust of healthcare institutions disproportionately affect marginalized border populations, reinforcing disparities in vaccine acceptance and coverage [29–31].”
Polymeric Delivery Vehicles for Nucleic Acid Vaccines: Design Strategies and Biological Barriers
Su, P., Yuan, H., Zhang, K., Dong, N., Fang, H., & Tian, H. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c09208
Tendencias en la disciplina de la Visualización de Información
Pérez–Montoro, M. (2022) · Anuario ThinkEPI · doi:10.3145/thinkepi.2022.e16a02
Jensen, L. R., Posa, M. R., Filipp, S. L., Kelly, M. N., & Otero, J. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2482513
“Safe and efficacious vaccines are instrumental in protecting these groups against the virus and are now available to patients six months and older [3,7–9].”
Micek, A., Diehl, K., Teuscher, M., Schaarschmidt, M., Sasama, B., Ohletz, J., Burbach, G. J., Kiecker, F., Hillen, U., Harth, W., et al. (2022) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14799_g
Ambivalent Safeties: Attending to Intersectional Marginalities in Vaccine Pharmacovigilance
Mezza, M. (2026) · Springer eBooks · doi:10.1007/978-981-95-8349-2_6
Castro‐Varela, A., Garza-Salas, A., Barrios‐Ruiz, A., Morales, E. A., Abascal-Lanzagorta, P., Reyes-Chavez, M. F., Cárdenas-Rodríguez, I. T., Solorzano-Lopez, E. J., Sánchez-Pizarro, C., Ríos-Arce, L. F. D. L., et al. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100407
“[20].”
In the midst of imbalance: medical and healthcare students versus SARS-CoV-2
Kamieniecki, A., Marek, D., Dułak, N. A., Skrzypkowska, P., Olofsson, H. K. L., Szmuda, T., Słoniewski, P., & Ali, S. (2022) · European Journal of Translational and Clinical Medicine · doi:10.31373/ejtcm/143211
Singh, P., Choudhary, R., Matreja, P. S., Patrick, S., Kumar, D., & Singh, V. K. (2023) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/jcmk/13528
Bacterial mRNA Vaccines: Programming Immunity Against Antimicrobial Resistance
Liao, R., Mingxing, L., Yang, F., Xu, L., Zhang, J., Zhang, W., Guan, S., Zhang, Y. M., Luo, P., Cheng, P., et al. (2026) · Drug Development Research · doi:10.1002/ddr.70335 · Cited by 2
A Tale of Two Scenarios: Vaccination's Impact on Covid-19 Trajectories in Jordan
Mahmud, A., & AbuQamar, Q. A. (2025) · Malaysian Journal of Medicine and Health Sciences · doi:10.47836/mjmhs.21.4.33
Recoding by N1-methylpseudouridine guides rational mRNA vaccine design
Poulis, P., Robecchi, G., Kurochkina, A., Felletti, M., & Rodnina, M. V. (2026) · Nature Communications · doi:10.1038/s41467-026-77796-3
Vélez-Páez, J. L., Kuonqui-Vera, Y., Castelo, J.-P., Rivadeneira-Bonifaz, G., Chango-Salas, C., Parreño, J., & Barriga, C. (2023) · Bionatura · doi:10.21931/rb/2023.08.01.48
Bayesian sequential probability ratio test for vaccine efficacy trials
Paul, E., Sutradhar, S., Hartzel, J. S., et al. (2024) · Computational Statistics · doi:10.1007/s00180-024-01458-5
“Such approaches were utilized in a number of the COVID-19 efficacy trials (Polack et al. 2020; Sadoff et al. 2021; Baden et al. 2021).”
Respuesta inmunológica a la vacunación y riesgo de COVID-19 en adultos con neoplasias hematológicas
Cortés, J. A., Nócua-Báez, L. C., Díaz‐Brochero, C., & Cuervo, S. I. (2023) · Revista chilena de infectología · doi:10.4067/s0716-10182023000300228 · Cited by 2
Toyonaga, H., Cheng, L., & Tanaka, H. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00982
Delamater, P. L., & Woodul, R. L. (2022) · medRxiv · doi:10.1101/2022.10.21.22281271 · Cited by 1
“We estimated that 80% of those who received both doses of an mRNA vaccine would develop immunity ( ρ 2 ) (Baden et al., 2021; Dagan et al., 2021; Polack et al., 2020).”
Franco, S., Trigueros, M., Palacín, D., Bonet, J. M., Isnard, M. D. M., Moreno, N., Mateu, L., Prat, N., Massanella, M., & Martínez, M. Á. (2024) · COVID · doi:10.3390/covid4080089
Chen, X., Fang, J., Ge, X., Li, M., Jiang, F., Yang, L., Hong, L., & Liu, Z. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115148 · Cited by 5
Clinical Trial Modernization: Technological, Operational, and Regulatory Advances
Buyse, M. E. (2026) · Journal of the American Statistical Association · doi:10.1080/01621459.2026.2675377
Ferenci, T., & Sarkadi, B. (2022) · Figshare · doi:10.6084/m9.figshare.19029488
Evaluation of Side Effects Associated with COVID-19 Vaccines in Pregnant Women
Mirzaie, F., Badakhsh, M., Nasab, M. B., & Mousaei, Z. (2023) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.37.54
“The information was collected using a questionnaire based on previous studies (4, 11-13).”
BackgroundMethodResultInfluentialBarilan, Y. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.002.0005
Zhou, Q., Eggert, T., Zhelyazkova, A., Choukèr, A., Adorjan, K., & Straube, A. M. (2024) · BMC Neurology · doi:10.1186/s12883-024-03583-6
“Additionally, several studies also describe that head-ache is the second most commonly occurring systemic side event, following fatigue [25–27].”
BackgroundDo I need a COVID-19 booster shot? 6 questions answered on how to stay protected
Petri, W. A. (2021) · The Conversation · doi:10.64628/aai.dkwa9grnh
Chua, J. X., Durrant, L. G., Chok, Y. L., & Lai, O. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4062765
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.